AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01610999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
Study NCT03683732 — intervention group
Intervention type: BEHAVIORAL
Intervention: Individual semi-structured interviews
Description: Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
Study NCT00179491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intercessory Prayer
Description: 14 days of intercessory prayer from 3 sites
Study NCT00179491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intercessory Prayer
Description: 14 days of intercessory prayer from 3 sites
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg will be administered as premedication prior to infusions.
Study NCT01943253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ESD
Description: Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
Study NCT01943253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybridknife ESD
Description: Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg will be administered as premedication prior to infusions.
Study NCT03227146 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHSG-KF
Description: Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
Study NCT03227146 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin graft to the control area
Study NCT02668471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
Study NCT02668471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional method
Description: Radial artery catheters will be placed by the palpation technique only.
Study NCT01989468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
Study NCT01548001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: 25 mg/tablet, taken orally, 2 tablets/day (bid)
Study NCT01548001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
Study NCT01548001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
Study NCT01693315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076
Study NCT01693315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01629797 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational script on Acne
Description: An educational script on Acne will be presented by investigator
Study NCT02470455 — intervention group
Intervention type: DRUG
Intervention: Atorvastatin
Description: Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
Study NCT02468648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
Study NCT02468648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5816
Description: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
Study NCT02521701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFL101
Description: Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL.
Study NCT01183624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Patch
Description: 1 herbal patch applied for approximately 8 hours per day for 14 days
Study NCT01183624 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Control patch with no herbal ingredients
Study NCT02634580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT02634580 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT02634580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Tablet for oral administration
Study NCT02634580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT02634580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ezetimibe
Description: Tablet for oral administration
Study NCT01197365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with GOS, beta-palmitate, acidified milk
Description: Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae
Study NCT01197365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard infant formula without functional ingredients
Description: Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
Study NCT03118297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
Study NCT03118297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
Study NCT02268435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib plus imatinib
Description: Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
Study NCT02821858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
Study NCT02821858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
Study NCT02821858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study NCT03934788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxysoft (olifilcon C)
Description: subjects meet certain criteria will be administered randomly oxysoft on both eye for one month on daily wear single use modality.
Study NCT03934788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Si-Hy (olifilcon B)
Description: subjects meet certain criteria will be administered randomly Si-Hy on both eye for one month on daily wear single use modality.
Study NCT02963805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity physical activity (HIPA)
Description: This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (\~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.
Study NCT02963805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fundamental movement skill (FMS)
Description: This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.
Study NCT02963805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity signposting (PASS)
Description: A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
Study NCT00847327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Support
Description: The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
Study NCT01989468 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Secukinumab placebo provided in 1 mL autoinjector
Study NCT02451371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
Study NCT00847327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
Study NCT01526668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up strategy
Description: Comparison of different follow-up strategies
Study NCT04340141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT04340141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT04340141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT04340141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT04340141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT01526668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No contact after discharge
Study NCT05276661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TAC/Collagen gel
Description: Apply it twice per day for 4 weeks
Study NCT05276661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo lotion
Description: Apply it twice per day for 4 weeks
Study NCT01820325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Study NCT01820325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buparlisib placebo
Description: Placebo + Carboplatin + Paclitaxel
Study NCT01820325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01820325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study NCT01820325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01820325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study NCT02170662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost
Description: Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
Study NCT02170662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03705182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence visualization (feedback)
Description: UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
Study NCT00720928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: flucinolone acetonide
Description: Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
Study NCT02401737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVR 3-778
Study NCT02401737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NVR 3-778
Description: Sugar pill manufactured to mimic the NVR 3-778 capsule
Study NCT02401737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Study NCT02401737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Study NCT04405375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabin
Description: 1.25g/㎡ d1, repeated every 21 days
Study NCT04405375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500IU/㎡ d1, total dose=\<3750IU, repeated every 21 days
Study NCT04405375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 75mg/㎡ d1-3, repeated every 21 days
Study NCT04405375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg d1-4
Study NCT02801214 — intervention group
Intervention type: OTHER
Intervention: fMRI
Study NCT00690885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha lozenges
Description: 150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks
Study NCT00690885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo lozenges
Description: matching placebo lozenges
Study NCT04224805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone-borne CAD/CAM splint
Description: 3D printed splint that repositions the maxilla with the zygomatic buttress as a reference.
Study NCT04224805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D interocclusal conventional splint
Description: Interocclusal splint that relies on the centric relation of the condyle as well as occlusion.
Study NCT01136499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589 (Panobinostat®)
Description: 40 mg MWF.~40 mg of LBH589, orally administered on Monday, Wednesday and Friday (MWF) on a weekly schedule, until tumor progression or unacceptable toxicity.
Study NCT00248703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 100 mg/m2 3 qw x 6
Study NCT00809380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental presence
Description: Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
Study NCT00809380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
Study NCT02710357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Overdenture
Description: Placement of an implant in the mandibular midline.
Study NCT02710357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular complete denture
Description: No intervention. Maintenance of the dentures will be done when needed.
Study NCT01484067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch ( Compeed© Total CareTM Cold Sore Patch)
Description: A cold sore patch containing zinc sulfate
Study NCT00159432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00159432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00159432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT00841763 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (PL)
Description: One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle, preferably of the non-dominant arm.
Study NCT00841763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine (TIV)
Description: A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
Study NCT00841763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted monovalent influenza virus vaccine (aH5N1)
Description: Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
Study NCT00841763 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted trivalent influenza virus vaccine (aTIV)
Description: Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.